Company news
Youcare Pharmaceutical Group Co. Ltd. news in 2026
Youcare Pharmaceutical Group Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Receipt of Approval from the FDA for Clinical Trials of Indications of YKYY018 Inhalation Aerosol in the Treatment and Prevention of Human Parainfluenza Virus Infection
November 12, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Report for Q3 2026
October 28, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 28, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Providing Guarantee for Wholly-owned Subsidiary
October 28, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 28, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Changes to Certain Raised Funds Investment Projects and Investment of Remaining Raised Funds and Remaining Over-raised Funds in New Raised Funds Investment Projects
October 28, 2026
(688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of the Receipt of Marketing Approval for the New Drug Zihua Wenfei Zhisou Granules
October 15, 2026
Announcement on Voluntary Disclosure of the Subsidiary's YKYY036 Injection Obtaining Clinical Trial Approvals from the National Medical Products Administration and the U.S. Food and Drug Administration
October 13, 2026
Announcement on Opening a Raised Funds Account and Signing a Supervision Agreement for Deposit of Raised Funds in Special Account
September 14, 2026
Announcement on the Use of a Portion of Over-raised Funds for Investment in New Projects
August 20, 2026
Announcement on Voluntary Disclosure of the Subsidiary's Receipt of FDA Clinical Trial Approval for YKYY033 Injection
August 12, 2026
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from NMPA for New Indication of YKYY017 Inhalation Aerosol
August 5, 2026
Announcement on the Unfreezing of Shares of the Controlling Shareholder
August 4, 2026
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from NMPA for New Indication of Subsidiary's YKYY033 Injection
July 21, 2026
Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections
June 26, 2026
Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application by a Subsidiary
June 17, 2026
Announcement on Unfreezing of Partial Shares Held by Controlling Shareholders
June 11, 2026
Announcement on Completing the Transfer Registration in Judicial Auction of Partial Shares Held by Controlling Shareholders
May 27, 2026
Announcement on Investment in Construction Project
May 7, 2026
Report for Q1 2026
April 29, 2026
Announcement on Opening a Raised Fund Account and Signing a Raised Fund Account Storage Supervision Agreement
April 21, 2026
Announcement on Progress in the 2nd Judicial Auction of a Portion of Company Shares Held by the Controlling Shareholder
April 14, 2026
Announcement on Voluntary Disclosure of Subsidiary’s YKYY025 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
April 13, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 10, 2026
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary
April 2, 2026
Announcement on Voluntary Disclosure of FDA Clinical Trial Approval for the Indication of YKYY018 Nebulized Inhalation for the Treatment and Prevention of Human Parainfluenza Virus Infection by Subsidiary
March 24, 2026
Announcement on Changing and Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Add Investment Projects Financed by Raised Funds and Permanently Supplement Current Capital
March 20, 2026
Announcement on the Failure of Judicial Auction of Partial Shares Held by Controlling Shareholders
March 17, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Indicative Announcement on Judicial Auction of Some Shares Held by Controlling Shareholders
February 25, 2026
Announcement on Resignation of Director and Senior Management Member and Election of Employee Director
February 13, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 6, 2026
Announcement on Expected Loss in Performance for 2025
January 30, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
January 21, 2026